Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Research

Combined and interactive effects of alcohol drinking and cigarette smoking on the risk of severe illness and poor clinical outcomes in patients with COVID-19: a multicentre retrospective cohort study

X.M. Fang \(a, b, \dagger, J.\) Wang \(a, b, \dagger, Y.\) Liu \(a, b, c, X.\) Zhang \(a, b, c, T.\) Wang \(a, H.P.\) Zhang \(a, b, c, Z.A.\) Liang \(a, F.M.\) Luo \(a, b, W.M.\) Li \(a, D.\) Liu \(a, **, \dagger, G.\) Wang \(a, b, *, \dagger, \)

\(a\) Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
\(b\) Laboratory of Pulmonary Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, Sichuan University, Chengdu, Sichuan 610041, China
\(c\) Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

\(\dagger\) These authors contributed equally to this work.
\(\dagger\) These senior authors contributed equally to this article.

A B S T R A C T

Objectives: Cigarette smoking is an established risk factor for illness severity and adverse outcomes in patients with COVID-19. Alcohol drinking may also be a potential risk factor for disease severity. However, the combined and interactive effects of drinking and smoking on COVID-19 have not yet been reported. This study aimed to examine the combined and interactive effects of alcohol drinking and cigarette smoking on the risk of severe illness and poor outcomes in patients with COVID-19.

Study design: This was a multicentre retrospective cohort study.

Methods: This study retrospectively reviewed the data of 1399 consecutive hospitalised COVID-19 patients from 43 designated hospitals. Patients were grouped according to different combinations of drinking and smoking status. Multivariate mixed-effects logistic regression models were used to estimate the combined and interactive effects of drinking and smoking on the risk of severe COVID-19 and poor clinical outcomes.

Results: In the study population, 7.3% were drinkers/smokers, 4.3% were drinkers/non-smokers and 4.9% were non-drinkers/smokers. After controlling for potential confounders, smokers or drinkers alone did not show a significant increase in the risk of severe COVID-19 or poor clinical outcomes compared with non-drinkers/non-smokers. Moreover, this study did not observe any interactive effects of drinking and smoking on COVID-19. Drinkers/smokers had a 62% increased risk (odds ratio = 1.62, 95% confidence interval: 1.01-2.60) of severe COVID-19 but did not have a significant increase in the risk for poor clinical outcomes compared with non-drinkers/non-smokers.

Conclusions: Combined exposure to drinking and smoking increases the risk of severe COVID-19, but no direct effects of drinking or smoking, or interaction effects of drinking and smoking, were detected.

Introduction

The COVID-19 pandemic is rapidly evolving worldwide.\(^{1,2}\) The clinical spectrum of COVID-19 appears to be wide, ranging from mild, moderate and severe to critical illnesses.\(^{3}\) Severe and critical cases are more likely to present with multiple organ dysfunction syndrome, acute respiratory distress syndrome (ARDS) and shock, thus contributing to intensive care unit (ICU) admission, mechanical ventilation (MV) and even death, and posing a serious threat to public health.\(^{4,5}\) Therefore, the risk factors for severe COVID-19 and
poor outcomes should be identified to improve the management of COVID-19 in clinical practice.

Several studies have investigated factors related to the severity of COVID-19 and its adverse outcomes. Smoking has received special attention as this is a well-established modifiable risk factor for many diseases.7,8 In relation to COVID-19, although the results are contradictory,7,8 smoking seems more likely to be associated with disease severity, negative progression and adverse outcomes of COVID-19.7,13–15 The results from a recent meta-analysis involving 22,939 COVID-19 patients reported that smoking is an independent risk factor for COVID-19 progression, including mortality.15 Drinking alcohol, a factor closely related to cigarette smoking, has been reported to be associated with poor outcomes of pneumonia patients and critically ill patients.14–16 However, little attention has been paid to the effects of drinking alcohol on the severity and clinical outcomes of COVID-19.

Alcohol drinking and smoking can cause damage to nearly all body organs and are globally the two most important preventable health risk factors, with an important impact on public health.7 Based on the report of the Global Burden of Disease study, drinking accounted for nearly 10% of global deaths among populations aged 15–49 years, while smoking accounted for 11.5% of global deaths.7,8,16–18 Furthermore, alcohol drinking and cigarette smoking, as two closely related factors, have various detrimental effects. Alcohol drinking and cigarette smoking have an interactive or combined effect on the treatment of pulmonary tuberculosis, the risk of lung cancer and many digestive malignancies and on all-cause and premature mortality.15,20–22 However, the association between combined smoking and drinking and COVID-19 has not yet been reported. Therefore, this study aimed to evaluate the combined and interactive effects of alcohol drinking and smoking on the risk of severe illness and poor clinical outcomes in patients with COVID-19, thereby providing a better understanding of the effects of alcohol drinking and smoking exposure in COVID-19 patients.

Methods

Study design and participants

Data from patients with COVID-19 from Sichuan Province and Wuhan City, China, were used in this multicentre retrospective cohort study. All patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to one of 43 designated hospitals in Sichuan and Wuhan between 14 January and 22 March 2020 were enrolled in the study. All patients with COVID-19 enrolled in this study were diagnosed according to the World Health Organisation (WHO) interim guidelines.23 SARS-CoV-2 infection was confirmed by laboratory tests using real-time reverse-transcription polymerase chain reaction or high-throughput sequencing. Confirmed cases referred to patients who had positive results on nasal and pharyngeal swab tests.23

Clinical data collection

All clinical data on demographic characteristics, underlying comorbidities, laboratory and radiological findings, and treatment and outcome information were retrospectively extracted from the medical records by members of the trained research team. A standardised form, a modified version of the International Severe Acute Respiratory and Emerging Infection Consortium forms, was used for data collection.23 The confidentiality of the information was maintained by removing personal identifiable information. After careful review of medical records, detailed information on patients’ demographic characteristics, pre-existing chronic comorbidities, computed tomographic (CT) images of the chest, laboratory indicators on admission, treatment and outcomes were collected. Data were abstracted and entered into a Microsoft Excel spreadsheet by trained researchers, and the results were then cross-checked by two researchers.

Exposure

Information on the smoking and alcohol drinking history of patients was collected from the electronic medical records. In terms of smoking status, patients were classified as smokers (including former smokers and current smokers) and non-smokers based on the self-reported information. Similarly, in terms of alcohol drinking status, patients were classified as drinkers (including current drinkers and former drinkers) and non-drinkers according to their self-reported information. Patients were divided into four groups as follows: group one included drinkers/smokers; group two included drinkers/non-smokers; group three included non-drinkers/smokers; and group four included non-drinkers/non-smokers.

Outcomes

The primary outcomes included two important events, one of which was severe illness of COVID-19, and the other was a composite endpoint of all-cause death, ICU admission or invasive/non-invasive MV occurring during hospitalisation. These events were combined into a binary coded composite adverse outcome variable, indicating that at least one of the events occurred during the period of hospitalisation. This composite measure was adopted because all individual components were considered as serious outcomes in a previous study of COVID-19.26 The disease severity of COVID-19 was evaluated based on the WHO living guidance for COVID-19 management.27 The clinical classification was as follows:

Critical cases: Defined as patients with ARDS, sepsis, septic shock or other conditions requiring life-sustaining therapies, such as MV or vasopressor therapy.

Severe cases: Defined as patients who met any of the following criteria: (1) respiratory distress (≥30 breaths/min) for adults; (2) oxygen saturation of ≤90% at room air; and (3) signs of severe respiratory distress.

Non-severe cases: Defined as patients who did not meet the criteria for diagnosing severe or critical cases.

In line with previous studies,28–30 severe COVID-19 in our study was defined as patients with severe or critical COVID-19.

The secondary outcomes were defined as the individual events of the primary composite outcome: namely, death (all-cause death after COVID-19 diagnosis), ICU admission and invasive/non-invasive MV during the period of hospitalisation.

Statistical analyses

Continuous variables were expressed as mean (standard deviation) or median (interquartile range [IQR]), as appropriate. Categorical variables were expressed as counts and percentages. Continuous variables were compared using the one-way analysis of variance or Kruskal–Wallis test; categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. Bonferroni’s correction was used for multiple comparisons. Multivariate mixed-effects logistic regression models were used to explore the association of alcohol drinking and cigarette smoking with outcomes. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were estimated. The details
Results

Demographic and clinical characteristics

Patients aged <18 years, pregnant women, patients who died on admission to hospital and patients with missing information on smoking and alcohol status were excluded. In total, 1399 patients were included in the final analysis (Fig. 1). As shown in Table 1, the median age of the cohort was 55 years (IQR: 41, 66); 47.9% of patients were men, 60.9% patients were from Wuhan, 56.3% had at least one comorbidity, and the median duration from onset of illness to hospital admission was 10 days (IQR: 5, 16).

Drinkers/smokers, drinkers/non-smokers, non-drinkers/smokers and non-drinkers/non-smokers accounted for 7.3% (n = 103), 4.3% (n = 61), 4.9% (n = 69) and 82.7% (n = 1166) of the total study participants, respectively. Notably, compared with non-drinkers/non-smokers, drinkers/smokers were more likely to be men, younger, live in the epidemic centre region (Wuhan) and have a shorter time from illness onset to hospitalisation. In addition, drinkers/smokers were more likely to show lower CURB-65 (confusion, uraemia, respiratory rate, blood pressure, age ≥65 years) scores on admission, with a higher incidence of hepatic dysfunction complications. Drinkers/non-smokers were less likely to receive antibiotic treatment (39.3% vs. 59.8%; P = 0.002) than non-drinkers/non-smokers.

Laboratory and radiological findings

After Bonferroni’s correction, the median eosinophil count (P = 0.006) and median platelet count (P = 0.005) were lower in the drinkers/non-smokers group than in the non-drinkers/non-smokers group. Compared with non-drinkers/non-smokers, the other three groups (drinkers/smokers, drinkers/non-smokers and non-drinkers/smokers) had higher levels of haemoglobin (P < 0.001, P < 0.001 and P = 0.001, respectively) and serum creatinine (P < 0.001, P = 0.005 and P = 0.004, respectively). Moreover, drinkers/smokers had higher levels of creatine kinase (P < 0.001) and albumin (P < 0.001) than patients in the non-drinkers/non-smokers group. With regard to markers of coagulation function, drinkers/smokers and drinkers/non-smokers showed a slightly longer activated partial thromboplastin time (P < 0.001 and P < 0.001, respectively) than non-drinkers/non-smokers. In addition, patients in the drinkers/smokers group were more likely to show abnormal findings on radiological CT images (Supplementary Table S1).

Severity and clinical outcomes

The incidence of severe COVID-19 was significantly higher in drinkers/smokers than in non-drinkers/non-smokers (40.8% vs. 29.4%; P = 0.016) after Bonferroni’s correction. However, no significant difference was observed in the composite outcome (comprised of MV, ICU admission and in-hospital death) or in any of these three outcomes alone (Fig. 2).

Mixed-effects logistic regression analyses

Compared with non-smokers, current smokers and/or former smokers did not have significant associations with severe COVID-19 or composite outcomes. Moreover, current and/or past alcohol consumption were not significant predictors of severe COVID-19 or composite outcomes. By adding the interaction term to the regression models, no interaction effects were observed between smoking and alcohol consumption and severe COVID-19 and poor outcomes (P-values of the interaction term of drinking and smoking were 0.30 and 0.10, respectively). With regard to the different combinations of smoking and alcohol drinking status, the present study shows that smoking alone or drinking alone was not associated with severe COVID-19 and composite outcomes. Furthermore, the results show no significant association between drinkers/smokers and an increased risk of composite outcomes. In contrast, drinkers/smokers were more likely to have severe COVID-19 compared with non-drinkers/non-smokers (OR = 1.62; 95% CI: 1.01, 2.60), after adjusting for all potential confounders, including age, sex, Carlson Comorbidity Index, CURB-65 scores, time from illness onset to hospital admission, level of hospital and using centre as a random effect (Tables 2 and 3). However, no significant associations were found between smoking and drinking and any of the secondary outcomes (ICU admission, MV and in-hospital death; Supplementary Tables S2, S3 and S4).

---

**Fig. 1.** Flowchart of participants with COVID-19 in this study. The study cohort was divided into four groups based on different combinations of alcohol drinking and smoking status.
Inconsistent results of existing studies may be due, at least partially, to differences in the study participants, study design, follow-up duration and data analysis, in addition to other unknown reasons. However, the exact duration and number of cigarettes smoked per day have not been reported in most studies. The inconsistent results are partially attributable to the difference in exposure dose and duration. To explain the association between smoking and COVID-19, further well-designed and population-based prospective studies are necessary. In addition, the hypothesis that nicotine may be protective against severe COVID-19 makes the association between smoking and COVID-19 more complex. To better understand the relationship between smoking and COVID-19, clinical trials on nicotine are warranted.

In terms of alcohol drinking, to the best of the authors’ knowledge, only a few studies have explored the association of alcohol consumption with severe COVID-19 and poor clinical outcomes in COVID-19 patients. Similar to the findings in the present study, Liu et al. and Dai et al. show that drinking alcohol is not related to the severity of COVID-19. The current finding, that drinking is not related to the severity of COVID-19, is consistent with results from previous studies. In addition, we observed that alcohol consumption was equally unrelated to poor clinical outcomes, including in-hospital death, MV and ICU admission of hospitalised COVID-19 patients, although some important confounding factors were adjusted. Considering the amount of alcohol consumption with severe COVID-19 and poor clinical outcomes in COVID-19 patients. Similar to the findings in the present study, Liu et al. and Dai et al. show that drinking alcohol is not related to the severity of COVID-19. The current finding, that drinking is not related to the severity of COVID-19, is consistent with results from previous studies. In addition, we observed that alcohol consumption was equally unrelated to poor clinical outcomes, including in-hospital death, MV and ICU admission of hospitalised COVID-19 patients, although some important confounding factors were adjusted. Considering the amount of alcohol consumption with severe COVID-19 and poor clinical outcomes in COVID-19 patients.

### Table 1

Demographics and clinical characteristics of COVID-19 patients.

| Variables                      | Drinkers/smokers | Drinkers/ non-smokers | Non-drinkers/smokers | Non-drinkers/ non-smokers | Total | χ²/df | P-value |
|--------------------------------|------------------|-----------------------|----------------------|---------------------------|-------|-------|---------|
| Total                          | 103 (7.3)        | 61 (4.3)              | 69 (4.9)             | 1166 (82.7)               | 1399  |       |         |
| Age (years)                    | 48.00 (38.00, 62.00) | 48.00 (34.00, 61.00) | 56.00 (34.00, 63.50) | 56.00 (42.00, 66.00)      | 55.00 (41.00, 66.00) | 16.106 | 0.001   |
| Male                           | 77 (74.8%)       | 48 (78.7%)            | 58 (84.1%)           | 487 (41.8%)               | 670 (47.9%) | 106.666 | <0.001  |
| Region                         |                  |                       |                      |                           |       |       |         |
| Sichuan                        | 21 (20.4%)       | 7 (11.5%)             | 31 (44.9%)           | 488 (41.9%)               | 547 (39.1%) | 39.388 | <0.001  |
| Wuhan                          | 82 (79.6%)       | 54 (88.5%)            | 38 (55.1%)           | 678 (58.1%)               | 852 (60.9%) |       |         |
| Allergic history               | 6 (5.8%)         | 7 (4.9%)              | 4 (7.2%)             | 36 (52.9%)                | 122 (85.5%) | 1.404  | 0.705   |
| CURB-65                        | 0.36 (0.73)      | 0.43 (0.74)           | 0.48 (0.72)          | 0.52 (0.74)               | 0.50 (0.74) | 6.826  | 0.035   |
| Any comorbidity                | 53 (52.0%)       | 32 (52.9%)            | 66 (52.9%)           | 602 (57.8%)               | 783 (56.3%) | 1.701  | 0.637   |
| CCI                            | 1.37 (2.23)      | 1.05 (1.53)           | 1.90 (2.592)         | 1.51 (2.03)               | 1.50 (2.06) | 4.052  | 0.256   |
| Complications                  | 62 (60.2%)       | 30 (49.2%)            | 39 (56.5%)           | 679 (58.2%)               | 810 (57.9%) | 2.232  | 0.132   |
| ARDS                           | 5 (4.9%)         | 4 (6.6%)              | 3 (4.3%)             | 37 (5.6%)                 | 40 (3.2%) | 1.404  | 0.705   |
| Pneumonia                      | 59 (57.3%)       | 25 (41.0%)            | 33 (47.8%)           | 554 (47.5%)               | 671 (48.0%) | 4.869  | 0.182   |
| Hepatic dysfunction            | 23 (22.3%)       | 11 (18.0%)            | 12 (17.4%)           | 129 (11.8%)               | 175 (12.5%) | 14.507 | 0.002   |
| Treatment                      |                  |                       |                      |                           |       |       |         |
| Antiviral treatment            | 98 (95.1%)       | 57 (93.4%)            | 60 (87.0%)           | 1070 (91.8%)              | 1285 (91.9%) | 3.920  | 0.027   |
| Antibiotics                    | 54 (52.4%)       | 24 (39.3%)            | 39 (56.5%)           | 697 (59.8%)               | 814 (58.2%) | 11.596 | 0.009   |
| High-flow oxygen therapy       | 5 (4.9%)         | 4 (6.6%)              | 3 (4.3%)             | 91 (1166) (7.8%)          | 103 (7.4%) | 2.261  | 0.052   |
| Corticosteroids                | 17 (16.5%)       | 11 (18.0%)            | 23 (33.3%)           | 307 (26.3%)               | 358 (25.6%) | 8.802  | 0.032   |
| Time from illness onset to ICU admission, days | 14.00 (8.00, 16.00) | 6.00 (5.00, 7.00) | 23.00 (14.50, 24.00) | 11.00 (7.50, 15.50) | 11.00 (7.00, 16.00) | 3.607  | 0.307   |
| Time from illness onset to hospital admission, days | 6.50 (3.00, 11.00) | 7.00 (3.00, 16.00) | 9.00 (4.00, 14.00) | 10.00 (5.75, 16.00) | 10.00 (5.00, 16.00) | 22.415 | <0.001  |
| Hospital length of stay, days  | 16.00 (9.25, 21.00) | 16.00 (13.00, 23.50) | 16.00 (10.00, 24.00) | 18.00 (10.00, 27.00) | 17.00 (10.00, 26.00) | 5.048  | 0.168   |
| Duration of viral shedding, days | 15.00 (9.00, 23.75) | 14.50 (11.75, 22.00) | 15.00 (9.50, 26.50) | 18.00 (12.00, 29.00) | 17.00 (11.00, 28.00) | 6.374  | 0.095   |
| Duration of corticosteroid treatment, days | 3.00 (1.75, 4.00) | 3.00 (2.00, 11.50) | 4.00 (1.50, 10.00) | 5.00 (3.00, 8.00) | 4.00 (3.00, 8.00) | 3.403  | 0.334   |

CCI, Carlson Comorbidity Index; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; CURB-65, confusion, uraemia, respiratory rate, blood pressure, age ≥65 years.

- **a** Data are expressed as median (IQR) or n (%), n/N (%), where N is the total number of patients with available data.
- **b** P-values comparing four groups are from χ², Fisher’s exact test or Kruskal-Wallis test. There are post-hoc comparisons.
- **c** Indicates P < 0.017. Bonferroni’s correction was used for multiple comparison with the non-drinkers/non-smokers group.
- **d** Shown as mean (standard deviation) because the median of CURB-65 and CCI was d.
- **e** Fisher’s exact test.
consumed, the results from Fan et al.’s study, based on a larger sample size, show that heavy drinkers with obesity were more likely to have worse COVID-19 clinical outcomes. Existing evidence demonstrating the association between alcohol consumption and COVID-19 is limited; it remains unclear whether alcohol drinking increases the risk of severe COVID-19 and poor clinical outcomes in COVID-19 patients. In the future, researchers should pay more attention to exploring whether alcohol drinking volume and time are associated with the severity and poor clinical outcomes of COVID-19.

Patients who smoke and drink alcohol are more vulnerable to COVID-19. Smoking can alter the structure of the respiratory tract and decrease the immune response, both systemically and locally within the lungs, increasing the risk of infections. Smoking has been shown to upregulate the expression of angiotensin-converting enzyme two receptor in the lungs, which is associated with increased SARS-CoV-2 attachment and entry into the alveolar epithelial cells, indicating a possible high-risk factor for COVID-19. Similarly, alcohol consumption, another important health risk factor, has been shown to alter the release of cytokines and functions of the barrier and ciliary fibres, thereby changing the defence capabilities of the airway epithelial host. Alcohol can also change the function of alveolar macrophages, affect the recruitment of neutrophils, weaken the phagocytosis of neutrophils to pathogens, and reduce the production and release of neutrophils into the circulating blood. Previous studies confirmed that consumption of alcohol causes an increased susceptibility to airway bacterial and viral infections, regardless of the exact underlying mechanism. Although the specific mechanism is not clear, it is likely that alcohol consumption also plays an important role in SARS-CoV-2 infection. In addition, both alcohol consumption and smoking trigger the production of the following substances, leading to oxidant stress: nitric oxide, carbon monoxide and phenolic free radicals, which have proven proinflammatory and could increase the likelihood of adverse clinical outcomes of COVID-19. Therefore, given their adverse effects on the lungs and immune system, as well as based on the results of previous studies on other bacterial and viral lung infections, it is reasonable to believe that, despite the lack of data, alcohol consumption and smoking may contribute to the COVID-19-related risk. Although the present study did not find interactive effects between smoking and drinking on COVID-19, combined exposure to drinking and smoking...
CI, con
large number of patients. The results reveal that drinkers/smokers in China. In addition, this was a multicentre study, with a relatively severe COVID-19 and the clinical outcomes of COVID-19 patients
the authors
developing severe COVID-19. However, the role of combined exposure to smoking and alcohol drinking as risk factors for severe COVID-19 among hospitalised COVID-19 patients is a preliminary finding; hence, further investigation of these results is necessary.

The present study has several notable strengths. To the best of the authors’ knowledge, this is the first study to investigate the interaction and combined effects of alcohol drinking and smoking on severe COVID-19 and the clinical outcomes of COVID-19 patients in China. In addition, this was a multicentre study, with a relatively large number of patients. The results reveal that drinkers/smokers had a higher risk of developing severe COVID-19 than non-drinkers/non-smokers.

The present study also has some limitations. First, the status of cigarette smoking and alcohol consumption was self-reported by the patients. Therefore, it is prone to recall bias. Second, the study had a retrospective observational design. Thus, the observed findings should be interpreted carefully because residual confounding cannot be entirely ruled out. For instance, obesity has been confirmed as an important risk factor for the severity and prognosis of COVID-19 patients; however, the information required to determine obesity was not collected, as body mass index data were missing. Third, exposure levels to alcohol and smoking were not provided; therefore, the impact of exposure levels to alcohol and smoking was not collected. In this study, the results were adjusted for age, sex, smoking status, level of hospital, duration from illness onset to hospital admission, CCI and CURB-65 scores on admission. The adjusted or unadjusted results were provided to illustrate the impact of confounders. The interaction of drinking and smoking was assessed using the multiplicative interaction approach.

### Table 2

Mixed-effects logistic regression models with centre as a random effect for severe COVID-19.

| Variables                        | Severe COVID-19<sup>a</sup> | Unadjusted | Adjusted |
|---------------------------------|-----------------------------|------------|----------|
|                                 | No, n (%)                   | Yes, n (%) | OR (95% CI) | OR (95% CI) |
| Drinking<sup>b</sup>            |                             |            |           |           |
| Non-drinkers                    | 361 (29.5)                  | 863 (70.5) | 1.00 (reference) | 1.00 (reference) |
| Current drinkers                | 38 (35.5)                   | 69 (64.5)  | 1.33 (0.76, 2.34) | 1.00 (0.52, 1.92) |
| Former drinkers                 | 22 (38.6)                   | 35 (61.4)  | 1.28 (0.84, 1.97) | 1.15 (0.67, 1.95) |
| Drinkers (current/former)       | 60 (36.6)                   | 104 (63.4) | 1.30 (0.91, 1.86) | 1.09 (0.69, 1.72) |
| Smoking<sup>c</sup>             |                             |            |           |           |
| Non-smokers                     | 357 (29.4)                  | 859 (70.6) | 1.00 (reference) | 1.00 (reference) |
| Current smokers                 | 43 (35.0)                   | 80 (65.0)  | 1.68 (0.93, 3.02) | 1.68 (0.84, 3.38) |
| Former smokers                  | 21 (42.9)                   | 28 (57.1)  | 1.27 (0.85, 1.89) | 1.24 (0.76, 2.03) |
| Smokers (current/former)        | 64 (37.2)                   | 108 (62.8) | 1.38 (0.98, 1.93) | 1.35 (0.87, 2.10) |
| Combined drinking and smoking<sup>d</sup> | 339 (29.4)                  | 816 (70.6) | 1.00 (reference) | 1.00 (reference) |
| Non-drinkers/non-smokers        | 18 (29.5)                   | 43 (70.5)  | 0.95 (0.53, 1.69) | 0.89 (0.48, 1.64) |
| Drinkers/non-smokers            | 22 (31.9)                   | 47 (68.1)  | 1.13 (0.67, 1.91) | 1.12 (0.64, 1.99) |
| Smokers (current/former)        | 42 (40.8)                   | 61 (59.2)  | 1.56 (1.02, 2.40) | 1.62 (1.01, 2.60) |

**Table 3**

Mixed-effects logistic regression models with centre as a random effect for composite poor outcome.

| Variables                        | Composite poor outcome<sup>e</sup> | Unadjusted | Adjusted |
|---------------------------------|-----------------------------------|------------|----------|
|                                 | No, n (%)                         | Yes, n (%) | OR (95% CI) | OR (95% CI) |
| Drinking<sup>b</sup>            |                                   |            |           |           |
| Non-drinkers                    | 1077 (87.2)                       | 158 (12.8) | 1.00 (reference) | 1.00 (reference) |
| Current drinkers                | 100 (93.5%)                       | 7 (6.5)    | 1.29 (0.59, 2.84) | 0.90 (0.35, 2.30) |
| Former drinkers                 | 49 (86.0)                         | 8 (14.0)   | 0.53 (0.24, 1.18) | 0.45 (0.18, 1.13) |
| Drinkers (current/former)       | 149 (90.9%)                       | 15 (9.1)   | 0.78 (0.44, 1.38) | 0.61 (0.30, 1.25) |
| Smoking<sup>c</sup>             |                                   |            |           |           |
| Non-smokers                     | 1075 (87.6)                       | 152 (12.4) | 1.00 (reference) | 1.00 (reference) |
| Current smokers                 | 110 (89.4)                        | 13 (10.6)  | 1.41 (0.64, 3.08) | 1.37 (0.53, 3.54) |
| Former smokers                  | 41 (83.7)                         | 8 (16.3)   | 0.94 (0.51, 1.73) | 1.07 (0.52, 2.22) |
| Smokers (current/former)        | 151 (87.8)                        | 21 (12.2)  | 1.08 (0.66, 1.77) | 1.16 (0.62, 2.18) |
| Combined drinking and smoking<sup>d</sup> | 1017 (87.2)                       | 149 (12.8) | 1.00 (reference) | 1.00 (reference) |
| Non-drinkers/non-smokers        | 58 (95.1)                         | 3 (4.9)    | 0.38 (0.12, 1.26) | 0.29 (0.08, 1.03) |
| Drinkers/non-smokers            | 60 (87.0)                         | 9 (13.0)   | 1.02 (0.49, 2.10) | 0.81 (0.27, 1.82) |
| drinkers/smockers               | 91 (88.3)                         | 12 (11.7)  | 1.04 (0.55, 1.99) | 0.91 (0.45, 1.84) |

Interaction of drinking and smoking

P for interaction<sup>e</sup> 0.39 0.30

CI, confidence interval; CCI, Carlson Comorbidity Index; CURB-65, confusion, uraemia, respiratory rate, blood pressure, age ≥65 years; OR, odds ratio.

<sup>a</sup> Severe COVID-19: including severe subtype and critical subtype.

<sup>b</sup> Adjusted for age, sex, smoking status, level of hospital, duration from illness onset to hospital admission, CCI and CURB-65 scores on admission.

<sup>c</sup> Adjusted for age, sex, smoking status, level of hospital, duration from illness onset to hospital admission, CCI and CURB-65 scores on admission.

<sup>d</sup> Adjusted for age, sex, level of hospital, the duration from illness onset to hospital admission, CCI and CURB-65 scores on admission.

<sup>e</sup> The P value represents the multiplicative interaction of drinking and smoking.
the dose–response relationship with COVID-19 cannot be explored. Fourth, a previous study has shown that the smoking rate in hospitalised patients with COVID-19 was lower than that of the general population. The present study only included a hospital-based population, which likely led to a greater imbalance between the number of patients in each group, thus possibly affecting the results and limiting the generalisation of results to other populations. Finally, because of the rapid and strict measures taken by the Sichuan provincial government to combat COVID-19, the sample size of most designated hospitals in Sichuan was relatively small. This limited the ability to control for hospital variability using hospital as a random effect. Therefore, further data are required that are more representative of the global population to validate these preliminary findings.

Conclusions

In conclusion, combined exposure to alcohol drinking and smoking is linked to severe COVID-19; however, drinking alone or smoking alone had no direct effects, and both drinking and smoking had no interaction effects. Intervention strategies for alcohol consumption and smoking are recommended to decrease the risk of severe COVID-19.

Author statements

Acknowledgements

The authors would like to thank all the patients who donated their data for this analysis and all medical staff working in the front line for taking care of the patients. The authors are indebted to the coordination of Ms. Jun Hua Li from the Health Commission of Sichuan Province and Mr. Nian Li and Ms. Bei Bai from West China Hospital, Sichuan University, who greatly facilitated the collection of patients’ data.

Ethical approval

This study was approved by the Biological and Medical Ethics Committee of West China Hospital (approval number: 2020-304 and 2020-126) and the Ethics Committee of Renmin Hospital of Wuhan University (approval number: WDRY2020-K068). Administrative permission to access the raw data was granted by administrators of each hospital. The study was a retrospective cohort design, and the data used in the study were anonymous, so the requirement for informed consent was waived.

Funding

This study was supported by the National Key Development Plan for Precision Medicine Research (2017YFC091004), the Sichuan Provincial Program for Diagnostic and Treatment of COVID-19 (No. 2020YS002 and 2020YS005) and the National Natural Science Foundation of China (No. 81920108002). Funding sources played no role in the study design, data analysis, decision to publish or preparation of the manuscript.

Competing interests

None declared.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhe.2022.01.013.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–33.
2. Poon LLM, Peiris M. Emergence of a novel human coronavirus threatening human health. Nat Med 2020;26(3):317–9.
3. Rees EM, Nightingale ES, Jafar Y, Waterlow NR, Clifford S, B. Pearson CA, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med 2020;18(1):270.
4. Shi M, Chen L, Yang Y, Zhang J, Xu J, Xu G, et al. Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: a multicenter descriptive study. J Clin Lab Anal 2020;34(9):e22415.
5. Wang Z, Deng H, Ou C, Liang J, Wang Y, Jang M, et al. Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19: a systematic review and meta-analysis without cases duplication. Medicine (Baltim) 2020;99(48):e23327.
6. Usman MS, Siddiqi TJ, Khan MS, Patel UK, Shahid I, Ahmed J, et al. Is there a smoker’s paradox in COVID-19? BMJ Evid Based Med 2021;26(6):279–84.
7. Faralinos K, Bosag PC, Giannouchos T, Naira R, Barbourani A, Poulas K. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct J 2021;18(1):9.
8. Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study. Clin Microbiol Infect 2020;26(9):1242–7.
9. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol 2021;93(2):1045–56.
10. Kang S, Gong X, Yuan Y. Association of smoking and cardiovascular disease with disease progression in COVID-19: a systematic review and meta-analysis. Epidemiol Infect 2021;149:1–26.
11. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res 2020;22(9):1653–6.
12. Hou H, Li Y, Zhang P, Wu J, Shi L, Xu J, et al. Smoking is independently associated with an increased risk for COVID–19 mortality: a systematic review and meta-analysis based on adjusted effect estimates. Nicotine Tob Res 2021;23(11):1947–51.
13. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis. BMC Publ Health 2021;21(1):1554.
14. Room R. Smoking and drinking as complementary behaviours. Biomed Pharmacother 2004;58(2):111–5.
15. Moss M, Bucker B, Moore FA, Moore EE, Parsons PE. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. JAMA 1996;276(1):50–4.
16. Saiz R, Ghali WA, Moskowitz MA. The impact of alcohol-related diagnoses on pneumonia outcomes. Arch Intern Med 1997;157(13):1446–52.
17. Singer MV, Feick P, Gerloff A. Alcohol and smoking. Dig Dis Sci 2011;56(2):177–83.
18. Griswold MG, Fullman N, Hawley C, Arian N, Zimmes SMR, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systems analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:1015–35.
19. Reitsma MB, Fullman N, Ng M, Salama JS, Ababou AB, Al-Shekh KH, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017;389(9):1885–906.
20. Ma Y, Che NY, Liu YH, Shu W, Du J, Xie SH, et al. The joint impact of smoking plus alcohol drinking on treatment of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis 2019;38(1):451–7.
21. Bagnardi V, Randi G, Lubin J, Consonni D, Lam TK, Subar AF, et al. Alcohol consumption and lung cancer risk in the environment and genetics in lung cancer etiology (EAGLE) study. Am J Epidemiol 2010;171(3):36–44.
22. Hopenh Z, Bi X, Zheng N, Li C, Yan K. Joint effect of alcohol drinking and tobacco smoking on all-cause mortality and premature death in China: a cohort study. PLoS One 2021;16(1):e0245670.
23. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. 25 January 2020. World Health Organization; 2020. https://apps.who.int/iris/handle/10665/330854.
24. Wang G, Luo FM, Liu D, Liu JS, Wang Y, Chen H, et al. Differences in the clinical characteristics and outcomes of COVID-19 patients in the epicenter and peripheral areas of the pandemic from China: a retrospective, large-sample, comparative analysis. BMC Infect Dis 2021;21(1):206.
25. International severe acute respiratory and emerging infection consortium COVID-19 clinical research resources. https://isarc.org/.
26. Vecchiet A, Chiabrando JG, Dell MS, Bonaventura A, Mauro AG, Wohlford G, et al. Clinical presentation and outcomes of acute pericarditis in a large urban hospital in the United States of America. Chest 2020;158(6):2556–67.
27. World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. World Health Organization; 2021. https://apps.who.int/iris/handle/10665/338882.
28. Tang A, Mantovani A, Wang XB, Yan HD, Sun QF, Pan KH, et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab 2020;46(4):335–7.
29. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. *J Infect* 2020;81(2):e16–25.
30. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. *J Med Virol* 2020;92(10):1915–21.
31. Ho KS, Narasimhan B, Sheehan J, Wu L, Fung JY. Controversy over smoking in COVID-19 - a real World experience in New York city. *J Med Virol* 2020;93(7):4537–43.
32. Dai M, Tao L, Chen Z, Tian Z, Guo X, Allen-Gipson D, et al. Influence of cigarettes and alcohol on the severity and death of COVID-19: a multicenter retrospective study in Wuhan, China. *Front Physiol* 2020;11:588553.
33. Adrish M, Chilimuri S, Mantri N, Sun H, Zahid M, Gongati S, et al. Association of smoking status with outcomes in hospitalised patients with COVID-19. *BMJ Open Respir Res* 2020;7(1):e000716.
34. Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, et al. Smoking and COVID-19: adding fuel to the flame. *Int J Mol Sci* 2020;21(18):6581.
35. Liu M, Gao Y, Shi S, Chen Y, Yang K, Tian J. Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis. *J Infect* 2020;81(2):e126–7.
36. Fan X, Liu Z, Poulsen KL, Wu X, Miyata T, Dasarathy S, et al. Alcohol consumption is associated with poor prognosis in obese patients with COVID-19: a Mendelian randomization study using UK biobank. *Nutrients* 2021;13(5):1592.
37. Arcavi L, Benowitz NL. Cigarette smoking and infection. *Arch Intern Med* 2004;164(20):2206–16.
38. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. *Am J Respir Crit Care Med* 2020;201(12):1557–9.
39. Curreli F, Victor SMB, Ahmed S, Drellich A, Tong X, Tseng CK, et al. Stapled peptides based on human angiotensin-converting enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro. *mBio* 2020;11(6).
40. Wyatt TA, Sisson JH. Chronic ethanol downregulates PKA activation and ciliary beating in bovine bronchial epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2001;281(3):L575–81.
41. Simet SM, Sisson JH. Alcohol’s effects on lung health and immunity. *Alcohol Res* 2015;37(2):199–208.
42. Welsh P, Woodward M, Rumley A, Lowe GJB. In: Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study, vol. 141; 2008. p. 852–61, 6.
43. Liang Y, Harris F, Brown LJ. Alcohol induced mitochondrial oxidative stress and alveolar macrophage dysfunction, vol. 2014; 2014. p. 371593.
44. Venza I, Visalli M, Oteri R, Teti D, Venza M. Combined effects of cigarette smoking and alcohol consumption on antioxidant/oxidant balance in age-related macular degeneration. *Aging Clin Exp Res* 2012;24(5):530–6.
45. Kaligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. *Obesity* 2020;28(7):1200–4.
46. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? *Intern Emerg Med* 2020;15(3):845–52.